Takeda

Northeastern University | November 30, 2016

Christophe Weber, pres­i­dent and CEO of Takeda Phar­ma­ceu­tical Com­pany Ltd., brings a global vision, a mul­ti­cul­tural per­spec­tive, and a long-term approach to run­ning the 235-year-old Japanese company....

BioSpace (a DHI Group, Inc. company) | January 18, 2017

Takeda Pharmaceutical Company Limited (TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully complete...

pharmaceutical-technology | February 17, 2017

Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn. The acquisition was concluded through a tender offer and subsequent merger of ARIAD with Takeda Pharmaceuticals USA’s wholly owned subsidiary Kiku Merger....

Pharmaceutical Technology | April 03, 2017

Japanese-based Takeda Pharmaceutical Company and Medicines for Malaria Venture in Switzerland (MMV) have signed an agreement to start a new joint research programme aimed at finding lead compounds for malaria treatment....